Grace Therapeutics Inc (GRCE) Stock Price, Quote & News

Company Profile

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgi...

Industry: Biotechnology

Sector: Healthcare

Phone: 609-322-1602

Website: www.gracetx.com

Address:

103 Carnegie Center, Suite 300, Princeton, United States

Joco8380 Sep. 30 at 2:47 PM

$NRXP is gaining the same kind of attention and bullish momentum as it did last year. The difference this time is that it’s much closer to reaching its goal and price target increased to $40. I believe it could climb past $5 over the next couple of weeks, moving steadily upward, with the potential for even better news along the way. @Atai @huma $OTLK $OMER $PLX $GRCE

2 · Reply

Tanny86 Sep. 29 at 7:29 PM

$GRCE Below 3 is a gift as per my research. And I am loading a a titanic for next 6 months till April 2026. Good luck!!

1 · Reply

HarveySpecter20 Sep. 29 at 7:06 PM

$OTLK bought around 40k shares here today, after BLA-resubmission news. Planning to add more, if we close that gap at around 0,98$ $NRXP ANDA-Submission today. With the ketamine shortage in the US, this is a long-term hold for me. $OMER Bought a little bit more on todays dip, for PDUFA Run. Great Potential IMO. $PLX still bagholding here, but kept adding during the last two weeks and averaged down a good bit. Hope to get back into green soon. $GRCE Watching 👀

3 · Reply

Greenpa Sep. 18 at 3:38 PM

$GRCE Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104 Big value if approved and labeled by FDA with this dosing. About as under the radar as a stock can be.

1 · Reply

History101 Sep. 12 at 2:06 AM

$GRCE from PR 8/27/2025: Acceptance of the NDA for review triggers the potential exercise of up to $7.6 million in warrants issued as part of a private placement the Company completed in September 2023. Under the terms of the September 2023 private placement, each warrant is exercisable for one share of common stock at an exercise price of $3.003 per share. These warrants are currently exercisable and will expire on the earlier of (i) the 60th day after the date of the acceptance by the FDA of an NDA for the Company's product candidate GTX-104 or (ii) September 25, 2028. Grace has obtained Orphan Drug Designation from the FDA for GTx-104, which generally provides seven years of marketing exclusivity in United States upon FDA approval of the NDA. Additionally, the Company believes that its U.S. and international patent estate will protect the market value of GTx-104 beyond marketing exclusivity

0 · Reply

alexpitti Sep. 5 at 9:51 PM

I should have a large position in UNDISCLOSED and not bother with $AUTL, but I have this obsession with Autolus. I know this stock shouldn't be this low. I just know it! It must reverse sometime soon. Also I'm way more bullish on $DCTH than $ABEO, but I don't like selling stocks I'm very bullish on just to slightly alter allocations (bad for taxes & stress). Delcath is actually my top idea, then Stereotaxis, then, UNDISCLOSED, then Abeona, then Autolus, and finally Grace (no position). $GRCE

3 · Reply

Greenpa Sep. 5 at 7:44 PM

$GRCE Hesitant to recommend an AI piece, but below NVIDIAmillionare post is quite informative. It provides details on two other drugs in pipeline that I did not know.

1 · Reply

NVDAMillionaire Sep. 5 at 3:35 PM

$GRCE Brilliant piece that captures GRCE's situation perfectly. So if you want to update your understanding of GRCE or get to know GRCE better, this is essential reading. https://beyondspx.com/quote/GRCE/grace-therapeutics-injecting-innovation-into-rare-disease-treatment-with-gtx-104-s-market-ascent-nasdaq-grce#analysis

1 · Reply

Greenpa Sep. 5 at 11:15 AM

$GRCE Nothing is certain in life and this is technically a binary bet, but it is hard to imagine how the FDA won’t approve a drug where trial shows the new formulation is safer and more effective. I can wait 8 months for the payoff, but in theory smart money should push price up to reflect odds sooner than that.

1 · Reply

BB_88_ Sep. 4 at 8:31 PM

$GRCE she will rise soon

0 · Reply

Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting

Sep 18, 2025, 8:30 AM EDT - 16 days ago

Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104

Sep 4, 2025, 8:00 AM EDT - 4 weeks ago

Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 8:00 AM EDT - 5 weeks ago

Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104

Aug 12, 2025, 8:00 AM EDT - 7 weeks ago

Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update

Jun 25, 2025, 8:00 AM EDT - 3 months ago

Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104

Jun 23, 2025, 8:00 AM EDT - 3 months ago

Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update

Jun 13, 2025, 8:00 AM EDT - 4 months ago

Grace Therapeutics to Participate in the 2025 BIO International Conference

Apr 9, 2025, 8:00 AM EDT - 6 months ago

Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104

Mar 11, 2025, 7:00 AM EDT - 7 months ago

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

MTNB

Feb 25, 2025, 8:00 AM EST - 7 months ago

Grace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 13, 2025, 8:00 AM EST - 8 months ago

Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update

Feb 10, 2025, 12:05 PM EST - 8 months ago

Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study

Feb 10, 2025, 8:05 AM EST - 8 months ago

Grace Therapeutics Announces Private Placement Financing of up to $30 Million

Feb 10, 2025, 8:01 AM EST - 8 months ago

Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH

Jan 7, 2025, 8:00 AM EST - 9 months ago

Grace Therapeutics to Participate in Upcoming Investor Events January 2025

Oct 25, 2024, 8:00 AM EDT - 1 year ago

Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.

Sep 25, 2024, 7:30 AM EDT - 1 year ago

Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104

Sep 5, 2024, 10:35 AM EDT - 1 year ago

Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 9, 2024, 8:00 AM EDT - 1 year ago

Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update

Jun 27, 2024, 4:05 PM EDT - 1 year ago

Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial

Jun 21, 2024, 8:00 AM EDT - 1 year ago

Acasti Announces Year-End 2024 Financial Results, Provides Business Update

May 28, 2024, 4:05 PM EDT - 1 year ago

Acasti Pharma to Attend BIO International Convention 2024

Feb 12, 2024, 8:00 AM EST - 1 year ago

Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights

Feb 1, 2024, 8:00 AM EST - 1 year ago

Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial

Dec 13, 2023, 8:00 AM EST - 1 year ago

Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024

Nov 13, 2023, 8:00 AM EST - 2 years ago

Acasti Announces Second Quarter 2024 Financial Results and Business Highlights

Oct 23, 2023, 8:00 AM EDT - 2 years ago

Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial

Oct 4, 2023, 8:00 AM EDT - 2 years ago

Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Acasti Announces $7.5 Million Private Placement Equity Financing

Sep 6, 2023, 8:00 AM EDT - 2 years ago

Acasti to Participate in the H.C. Wainwright Global Investment Conference

Aug 11, 2023, 7:00 AM EDT - 2 years ago

Acasti Announces First Quarter 2024 Financial Results and Business Highlights

Aug 9, 2023, 4:05 PM EDT - 2 years ago

Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting

Jul 10, 2023, 9:00 AM EDT - 2 years ago

Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients

Jul 7, 2023, 8:00 AM EDT - 2 years ago

Acasti Pharma Announces 1-for-6 Reverse Stock Split

Jul 5, 2023, 9:00 AM EDT - 2 years ago

Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023

Jun 23, 2023, 7:00 AM EDT - 2 years ago

Acasti Pharma Reports Fiscal Year 2023 Operational Results

Jun 22, 2023, 9:00 AM EDT - 2 years ago

Acasti Announces Appointment of New Scientific Advisory Board Members

May 17, 2023, 9:00 AM EDT - 2 years ago

Acasti to Participate in the Lytham Partners Spring 2023 Investor Conference

May 8, 2023, 7:00 AM EDT - 2 years ago

Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025

Apr 4, 2023, 8:01 AM EDT - 2 years ago

Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND

Apr 4, 2023, 8:00 AM EDT - 2 years ago

Acasti Announces Appointment of Prashant Kohli as CEO

Mar 30, 2023, 8:30 AM EDT - 2 years ago

Acasti Pharma Inc. Announces the Resignation of a Director

Mar 13, 2023, 8:00 AM EDT - 2 years ago

Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange

Mar 8, 2023, 9:00 AM EST - 2 years ago

Acasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare Conference

Feb 28, 2023, 1:00 PM EST - 2 years ago

Acasti Pharma Recognizes Rare Disease Day

Feb 14, 2023, 3:53 PM EST - 2 years ago

Acasti Pharma Inc. (ACST) Q3 2023 Earnings Call Transcript

Feb 14, 2023, 7:00 AM EST - 2 years ago

Acasti Pharma Reports Third Quarter 2023 Operational Results

Feb 7, 2023, 9:00 AM EST - 2 years ago

Acasti Pharma to Report Third Quarter 2023 Financial Results on Tuesday, February 14, 2023

Jan 25, 2023, 9:00 AM EST - 2 years ago

Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule

Joco8380 Sep. 30 at 2:47 PM

2 · Reply

Tanny86 Sep. 29 at 7:29 PM

$GRCE Below 3 is a gift as per my research. And I am loading a a titanic for next 6 months till April 2026. Good luck!!

1 · Reply

HarveySpecter20 Sep. 29 at 7:06 PM

3 · Reply

Greenpa Sep. 18 at 3:38 PM

$GRCE Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104 Big value if approved and labeled by FDA with this dosing. About as under the radar as a stock can be.

1 · Reply

History101 Sep. 12 at 2:06 AM

0 · Reply

alexpitti Sep. 5 at 9:51 PM

3 · Reply

Greenpa Sep. 5 at 7:44 PM

$GRCE Hesitant to recommend an AI piece, but below NVIDIAmillionare post is quite informative. It provides details on two other drugs in pipeline that I did not know.

1 · Reply

NVDAMillionaire Sep. 5 at 3:35 PM

1 · Reply

Greenpa Sep. 5 at 11:15 AM

1 · Reply

BB_88_ Sep. 4 at 8:31 PM

$GRCE she will rise soon

0 · Reply

alexpitti Sep. 2 at 1:02 AM

$GRCE operation keep the stock above $3.003 commences

0 · Reply

Manonfire8 Aug. 27 at 7:23 PM

$GRCE this looks like a sell to the warrant price of 3.003. Probably uptrend forms after this

0 · Reply

alexpitti Aug. 27 at 5:40 PM

$GRCE ok sorry approval date is april 23rd. huge news

1 · Reply

shade00tree Aug. 27 at 5:27 PM

$GRCE

0 · Reply

Manonfire8 Aug. 27 at 4:29 PM

$GRCE I closed my $ESPR position to load into this 😒 wtf

2 · Reply

bdetweiler Aug. 27 at 2:57 PM

$GRCE Ok I hate this stock.

0 · Reply

nevercool Aug. 27 at 2:43 PM

$GRCE should be lifting... Still

0 · Reply

JujuInvestor2013 Aug. 27 at 12:34 PM

$GRCE very good news for grace… let’s see how the market reacts 😉🙏🚀 https://www.gurufocus.com/news/3081590/grace-therapeutics-announces-us-food-and-drug-administration-acceptance-for-review-of-new-drug-application-for-gtx104-grce-stock-news

1 · Reply

EagleShares Aug. 27 at 12:29 PM

$GRCE get to digging everybody, this is working out great. News are 👌

0 · Reply

TA_Kongen Aug. 27 at 12:11 PM

$GRCE Volume watch. Warrants active now due to news. 3.39 exercise from Private Placement.

1 · Reply

Greenpa Aug. 27 at 12:11 PM

$GRCE Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104 April 23,2026 PDUFA date. I believe that is accelerated beyond normal 10 months. Looks VERY promising.

0 · Reply

Stratyx Aug. 26 at 11:38 PM

$GRCE NDA acceptance is big news because it validates that the filing is solid, driving investor interest. Especially considering it leads directly to an FDA approval

1 · Reply

Market Cap	41.76M
Revenue (ttm)	0.00
Net Income (ttm)	-9.57M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	27,300
Avg Vol	85,174
Day's Range	N/A - N/A
Shares Out	13.83M
Stochastic %K	50%
Beta	1.00
Analysts	Strong Sell
Price Target	$11.83